Sollis Therapeutics Announces the First Patient Enrolled in a Phase 3 Clinical Trial of Clonidine Micropellet for Sciatica

Friday, November 16, 2018 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

COLUMBUS, Ohio, Nov. 16, 2018 /PRNewswire/ -- Sollis Therapeutics, Inc., an Ohio-based interventional

pain therapeutics company, announced that the first patient was enrolled in the RePRIEVE-CM trial, a Phase 3 clinical trial evaluating the efficacy and safety of the extended release non-opioid, non-steroid clonidine micropellet for the treatment of
sciatica pain.

The first subject was enrolled by Dr. Richard Vaglienti, Principal Investigator and Director of the Center for Integrative Pain Management at West Virginia University, who commented, "WVU is committed to doing our part to halt opioid misuse in our state and nationwide. Enrolling the first subject in the RePRIEVE-CM trial demonstrates our focus in working with companies such as Sollis to make a difference."

The RePRIEVE-CM (Radicular Pain RelIEf Via Epidural injection of Clonidine Micropellets) Trial will enroll 200 subjects at up to 30 U.S. sites and will compare the effect of the clonidine micropellet against a sham control for relief of sciatica pain. Sciatica affects approximately 5% of U.S. adults annually and is most commonly caused by a herniated intervertebral disc. There are no FDA approved medicines to treat sciatica and many patients receive opioids or steroid injections. The Sollis therapy is a novel non-opioid, non-steroid treatment delivered by a single injection and has the potential to treat sciatica pain for up to one year.

The overall study Principal Investigator, Dr. Christopher Gilligan, Chief of the Pain Medicine Division at Brigham and Women's Hospital and Assistant Professor at Harvard Medical School stated, "Every year more than a million patients receive unapproved and potentially risky treatments for this severely painful condition. We believe the clonidine micropellet will be a major step forward for these patients."

"We are eager to bring a non-addictive treatment to patients suffering from sciatica pain and are proud to partner with institutions such as WVU in taking a lead role to combat the opioid challenges so heavily affecting the nation. Entering the first subject into the RePRIEVE-CM trial of our non-opioid, non-steroid treatment for sciatica represents a key milestone for these patients as well as for the Sollis team," said Dr. Gregory Fiore, President and CEO of Sollis Therapeutics.

About Sollis Therapeutics

Sollis Therapeutics is a Columbus, Ohio based interventional pain therapeutics company focused on developing novel non-steroid, non-opioid analgesics.  Sollis' first product is an innovative extended release micropellet formulation of clonidine, an analgesic and anti-inflammatory medication purpose-built for targeted local delivery to treat sciatica and other neuropathic pain syndromes.

To learn more about Sollis, please visit www.Sollistx.com.

To learn more about the RePRIEVE-CM trial, please visit www.clinicaltrials.gov.

Cision View original content:http://www.prnewswire.com/news-releases/sollis-therapeutics-announces-the-first-patient-enrolled-in-a-phase-3-clinical-trial-of-clonidine-micropellet-for-sciatica-300752141.html

SOURCE Sollis Therapeutics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store